In the IMpassion130 study [5], atezolizumab combined with nab-paclitaxel showed improved PFS and clinically meaningful OS benefit versus placebo combined with nab-paclitaxel for patients with mTNBC with PD-L1 ≥ 1% expression on tumor-infiltrating immune cells. Here, CD274 is linked to neoplasm.